The oral antimalarial drug tafenoquine shows activity against Trypanosoma brucei

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6151-6160

  Carvalho, Luis ^a,d   Martínez García, Marta ^a   Pérez Victoria, Ignacio ^b   Manzano, José Ignacio ^a   Yardley, Vanessa ^c   Gamarro, Francisco ^a   Pérez Victoria, José M ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b Health Sciences Technology Park   (Spain)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; REACTIVE OXYGEN METABOLITE; TAFENOQUINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CELL DEATH; CELL MEMBRANE; CELL MEMBRANE DEPOLARIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOPLASM; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; IN VITRO STUDY; LYSOSOME; MEMBRANE DAMAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA BRUCEI; DRUG EFFECTS; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; TRYPANOSOMA BRUCEI BRUCEI; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; AMINOQUINOLINES; ANTIMALARIALS; HUMANS; LYSOSOMES; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84942931350     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00879-15     Document Type: Article

References (51)

1. World Health Organization. 2013. New phase in fight against neglected tropical diseases heralds universal access to health interventions for world's poorest. World Health Organization, Geneva, Switzerland. http://www.who.int/neglected-diseases/2012report/en/
2. Phillips MA. 2012. Stoking the drug target pipeline for human African trypanosomiasis. Mol Microbiol 86:10-14. http://dx.doi.org/10.1111/mmi.12001.
3. Babokhov P, Sanyaolu AO, Oyibo WA, Fagbenro-Beyioku AF, Iriemenam NC. 2013. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health 107:242-252. http://dx.doi.org/10.1179/2047773213Y.0000000105.
4. Kennedy PG. 2013. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet Neurol 12:186-194. http://dx.doi.org/10.1016/S1474-4422(12)70296-X.
5. Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. 2010. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 4:e720. http://dx.doi.org/10.1371/journal.pntd.0000720.
6. Rodgers J, Jones A, Gibaud S, Bradley B, McCabe C, Barrett MP, Gettinby G, Kennedy PG. 2011. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl Trop Dis 5:e1308. http://dx.doi.org/10.1371/journal.pntd.0001308.
7. Kennedy PG. 2012. An alternative form of melarsoprol in sleeping sickness. Trends Parasitol 28:307-310. http://dx.doi.org/10.1016/j.pt.2012.05.003.
8. Burri C. 2012. An alternative form of melarsoprol in sleeping sickness: is an old drug always the best basis for a new one? Trends Parasitol 28:354-355. http://dx.doi.org/10.1016/j.pt.2012.06.002.
9. Law GL, Tisoncik-Go J, Korth MJ, Katze MG. 2013. Drug repurposing: a better approach for infectious disease drug discovery? Curr Opin Immunol 25:588-592. http://dx.doi.org/10.1016/j.coi.2013.08.004.
10. Price RN, Nosten F. 2014. Single-dose radical cure of Plasmodium vivax: a step closer. Lancet 383:1020-1021. http://dx.doi.org/10.1016/S0140-6736(13)62672-0.
11. Fernando D, Rodrigo C, Rajapakse S. 2011. Primaquine in vivax malaria: an update and review on management issues. Malar J 10:351. http://dx.doi.org/10.1186/1475-2875-10-351.
12. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Mohrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L. 2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383: 1049-1058. http://dx.doi.org/10.1016/S0140-6736(13)62568-4.
13. Medicines for Malaria Venture. 2014. Understanding delivery management of P. vivax malaria. Medicines for Malaria Venture, Geneva, Switzerland. http://www.mmv.org/access-delivery/access-portfolio/understanding-clinical-management-p-vivax-malaria.
14. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, Baird K, Moyes C, Howes R, Menard D, Bancone G, Winasti-Satyahraha A, Vestergaard LS, Green J, Domingo G, Yeung S, Price R. 2013. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J 12:112. http://dx.doi.org/10.1186/1475-2875-12-112.
15. Yardley V, Gamarro F, Croft SL. 2010. Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine. Antimicrob Agents Chemother 54:5356-5358. http://dx.doi.org/10.1128/AAC.00985-10.
16. Carvalho L, Luque-Ortega JR, Manzano JI, Castanys S, Rivas L, Gamarro F. 2010. Tafenoquine, an antiplasmodial 8-aminoquinoline, targets Leishmania respiratory complex III and induces apoptosis. Antimicrob Agents Chemother 54:5344-5351. http://dx.doi.org/10.1128/AAC.00790-10.
17. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R. 1997. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop 68:139-147. http://dx.doi.org/10.1016/S0001-706X(97)00079-X.
18. Manzano JI, Carvalho L, Perez-Victoria JM, Castanys S, Gamarro F. 2011. Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major. Antimicrob Agents Chemother 55:1045-1052. http://dx.doi.org/10.1128/AAC.01545-10.
19. Perez-Victoria JM, Cortes-Selva F, Parodi-Talice A, Bavchvarov BI, Perez-Victoria FJ, Munoz-Martinez F, Maitrejean M, Costi MP, Barron D, Di Pietro A, Castanys S, Gamarro F. 2006. Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to miltefosine by inhibiting drug efflux. Antimicrob Agents Chemother 50:3102-3110. http://dx.doi.org/10.1128/AAC.00423-06.
20. Divo AA, Patton CL, Sartorelli AC. 1993. Evaluation of rhodamine 123 as a probe for monitoring mitochondrial function in Trypanosoma brucei spp. J Eukaryot Microbiol 40:329-335. http://dx.doi.org/10.1111/j.1550-7408.1993.tb04924.x.
21. Wilkes JM, Mulugeta W, Wells C, Peregrine AS. 1997. Modulation of mitochondrial electrical potential: a candidate mechanism for drug resistance in African trypanosomes. Biochem J 326(Pt 3):755-761.
22. t'Kindt R, Jankevics Scheltema A, Zheng RA, Watson L, Dujardin DG, Breitling JC, Coombs R, Decuypere GHS. 2010. Towards an unbiased metabolic profiling of protozoan parasites: optimization of a Leishmania sampling protocol for HILIC-Orbitrap analysis. Anal Bioanal Chem 398:2059-2069. http://dx.doi.org/10.1007/s00216-010-4139-0.
23. Goldshmidt H, Matas D, Kabi A, Carmi S, Hope R, Michaeli S. 2010. Persistent ER stress induces the spliced leader RNA silencing pathway (SLS), leading to programmed cell death in Trypanosoma brucei. PLoS Pathog 6:e1000731. http://dx.doi.org/10.1371/journal.ppat.1000731.
24. Lopez-Martin C, Perez-Victoria JM, Carvalho L, Castanys S, Gamarro F. 2008. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrob Agents Chemother 52:4030-4036. http://dx.doi.org/10.1128/AAC.00964-08.
25. Mathis AM, Bridges AS, Ismail MA, Kumar A, Francesconi I, Anbazhagan M, Hu Q, Tanious FA, Wenzler T, Saulter J, Wilson WD, Brun R, Boykin DW, Tidwell RR, Hall JE. 2007. Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes. Antimicrob Agents Chemother 51:2801-2810. http://dx.doi.org/10.1128/AAC.00005-07.
26. Coppens I, Baudhuin P, Opperdoes FR, Courtoy PJ. 1993. Role of acidic compartments in Trypanosoma brucei, with special reference to lowdensity lipoprotein processing. Mol Biochem Parasitol 58:223-232. http://dx.doi.org/10.1016/0166-6851(93)90044-X.
27. Docampo R, Ulrich P, Moreno SN. 2010. Evolution of acidocalcisomes and their role in polyphosphate storage and osmoregulation in eukaryotic microbes. Philos Trans R Soc Lond B Biol Sci 365:775-784. http://dx.doi.org/10.1098/rstb.2009.0179.
28. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. 1974. Commentary. Lysosomotropic agents. Biochem Pharmacol 23: 2495-2531. http://dx.doi.org/10.1016/0006-2952(74)90174-9.
29. Golstein P, Kroemer G. 2007. Cell death by necrosis: toward a molecular definition. Trends Biochem Sci 32:37-43. http://dx.doi.org/10.1016/j.tibs.2006.11.001.
30. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G. 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16:3-11. http://dx.doi.org/10.1038/cdd.2008.150.
31. Kessler RL, Soares MJ, Probst CM, Krieger MA. 2013. Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell death. PLoS One 8:e55497. http://dx.doi.org/10.1371/journal.pone.0055497.
32. Vercesi AE, Docampo R, Moreno SN. 1992. Energization-dependent Ca2- accumulation in Trypanosoma brucei bloodstream and procyclic trypomastigotes mitochondria. Mol Biochem Parasitol 56:251-257. http://dx.doi.org/10.1016/0166-6851(92)90174-I.
33. Nolan DP, Voorheis HP. 1992. The mitochondrion in bloodstream forms of Trypanosoma brucei is energized by the electrogenic pumping of protons catalyzed by the F1F0-ATPase. Eur J Biochem 209:207-216. http://dx.doi.org/10.1111/j.1432-1033.1992.tb17278.x.
34. Schnaufer A, Clark-Walker GD, Steinberg AG, Stuart K. 2005. The F1-ATP synthase complex in bloodstream stage trypanosomes has an unusual and essential function. EMBO J 24:4029-4040. http://dx.doi.org/10.1038/sj.emboj.7600862.
35. Lanteri CA, Tidwell RR, Meshnick SR. 2008. The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei. Antimicrob Agents Chemother 52: 875-882. http://dx.doi.org/10.1128/AAC.00642-07.
36. Tielens AG, van Hellemond JJ. 2009. Surprising variety in energy metabolism within Trypanosomatidae. Trends Parasitol 25:482-490. http://dx.doi.org/10.1016/j.pt.2009.07.007.
37. Barrett MP, Boykin DW, Brun R, Tidwell RR. 2007. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152:1155-1171. http://dx.doi.org/10.1038/sj.bjp.0707354.
38. Nargund S, Joffe ME, Tran D, Tugarinov V, Sriram G. 2013. Nuclear magnetic resonance methods for metabolic fluxomics. Methods Mol Biol 985:335-351. http://dx.doi.org/10.1007/978-1-62703-299-5-16.
39. Hardin CD, Finder DR. 1998. Glycolytic flux in permeabilized freshly isolated vascular smooth muscle cells. Am J Physiol 274:C88-C96.
40. Coustou V, Biran M, Breton M, Guegan F, Riviere L, Plazolles N, Nolan D, Barrett MP, Franconi JM, Bringaud F. 2008. Glucose-induced remodeling of intermediary and energy metabolism in procyclic Trypanosoma brucei. J Biol Chem 283:16342-16354. http://dx.doi.org/10.1074/jbc .M709592200.
41. Xi Y, de Ropp JS, Viant MR, Woodruff DL, Yu P. 2008. Improved identification of metabolites in complex mixtures using HSQC NMR spectroscopy. Anal Chim Acta 614:127-133. http://dx.doi.org/10.1016/j.aca.2008.03.024.
42. Docampo R, Lukes J. 2012. Trypanosomes and the solution to a 50-year mitochondrial calcium mystery. Trends Parasitol 28:31-37. http://dx.doi.org/10.1016/j.pt.2011.10.007.
43. Xiong ZH, Ruben L. 1996. Nuclear calcium flux in Trypanosoma brucei can be quantified with targeted aequorin. Mol Biochem Parasitol 83: 57-67. http://dx.doi.org/10.1016/S0166-6851(96)02750-8.
44. Schanne FA, Kane AB, Young EE, Farber JL. 1979. Calcium dependence of toxic cell death: a final common pathway. Science 206:700-702. http://dx.doi.org/10.1126/science.386513.
45. Trump BF, Berezesky IK. 1992. The role of cytosolic Ca2+ in cell injury, necrosis and apoptosis. Curr Opin Cell Biol 4:227-232. http://dx.doi.org/10.1016/0955-0674(92)90037-D.
46. Ridgley EL, Xiong ZH, Ruben L. 1999. Reactive oxygen species activate a Ca2+-dependent cell death pathway in the unicellular organism Trypanosoma brucei brucei. Biochem J 340(Pt 1):33-40.
47. Smirlis D, Duszenko M, Ruiz AJ, Scoulica E, Bastien P, Fasel N, Soteriadou K. 2010. Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death. Parasit Vectors 3:107. http://dx.doi.org/10.1186/1756-3305-3-107.
48. Moreira W, Leprohon P, Ouellette M. 2011. Tolerance to druginduced cell death favors the acquisition of multidrug resistance in Leishmania. Cell Death Dis 2:e201. http://dx.doi.org/10.1038/cddis .2011.83.
49. Manzano JI, Garcia-Hernandez R, Castanys S, Gamarro F. 2013. A new ABC half-transporter in Leishmania major is involved in resistance to antimony. Antimicrob Agents Chemother 57:3719-3730. http://dx.doi.org/10.1128/AAC.00211-13.
50. Fullerton M, Singha UK, Duncan M, Chaudhuri M. 2015. Downregulation of Tim50 in Trypanosoma brucei increases tolerance to oxidative stress. Mol Biochem Parasitol 199:9-18. http://dx.doi.org/10.1016/j.molbiopara.2015.03.002.
51. Lu J, Vodnala SK, Gustavsson AL, Gustafsson TN, Sjoberg B, Johansson HA, Kumar S, Tjernberg A, Engman L, Rottenberg ME, Holmgren A. 2013. Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase of Trypanosoma brucei. J Biol Chem 288:27456-27468. http://dx.doi.org/10.1074/jbc.M113.495101